18 November 2015 - NICE has published draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high cholesterol (primary hypercholesterolaemia - heterozygous-familial and non-familial) and mixed dyslipidaemia.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-issues-draft-guidance-on-evolocumab-for-lipid-disorder